Is it Time to Dump Chimerix Inc (CMRX) Stock After it Has Fallen 5.58% in a Week?

Chimerix Inc (CMRX) stock is lower by 5.58% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Chimerix Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CMRX!

See Full CMRX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CMRX Stock Today?

Chimerix Inc (CMRX) stock has fallen -4.7% while the S&P 500 has gained 0.26% as of 2:05 PM on Monday, Apr 18. CMRX is lower by -$0.22 from the previous closing price of $4.79 on volume of 1,211,183 shares. Over the past year the S&P 500 has gained 5.79% while CMRX is lower by -41.18%. CMRX lost -$2.04 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Chimerix Inc click here.

More About Chimerix Inc

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Click Here to get the full Stock Report for Chimerix Inc stock.